NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free MCRB Stock Alerts $0.56 -0.02 (-3.45%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$0.54▼$0.6150-Day Range$0.56▼$1.2352-Week Range$0.54▼$6.73Volume3.73 million shsAverage Volume3.68 million shsMarket Capitalization$84.55 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Seres Therapeutics alerts: Email Address Seres Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,090.7% Upside$6.67 Price TargetShort InterestBearish12.45% of Shares Sold ShortDividend StrengthN/ASustainability-1.14Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$20,371 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.15) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.51 out of 5 starsMedical Sector263rd out of 911 stocksPharmaceutical Preparations Industry105th out of 410 stocks 3.3 Analyst's Opinion Consensus RatingSeres Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.45% of the outstanding shares of Seres Therapeutics have been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Seres Therapeutics has recently increased by 2.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Seres Therapeutics is -1.14. Previous Next 2.0 News and Social Media Coverage News SentimentSeres Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Seres Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 19 people have searched for MCRB on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows13 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,371.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seres Therapeutics are expected to grow in the coming year, from ($1.15) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Seres Therapeutics Stock (NASDAQ:MCRB)Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More MCRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MCRB Stock News HeadlinesApril 16, 2024 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average of $0.91April 9, 2024 | businesswire.comSeres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTApril 20, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 28, 2024 | finance.yahoo.comIncreases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for nowMarch 11, 2024 | finance.yahoo.comMCRB Apr 2024 1.000 putMarch 7, 2024 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | realmoney.thestreet.comSeres Therapeutics price target lowered by $4 at Oppenheimer, here's whyMarch 6, 2024 | markets.businessinsider.comSeres Therapeutics (MCRB) Gets a Buy from TD CowenApril 20, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 6, 2024 | finance.yahoo.comQ4 2023 Seres Therapeutics Inc Earnings CallMarch 5, 2024 | investorplace.comMCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023March 5, 2024 | investorplace.comGold Price Alert: Gold Spot Prices Just Hit a Record High TodayMarch 5, 2024 | msn.comSeres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23MMarch 5, 2024 | finance.yahoo.comSeres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 5, 2024 | finance.yahoo.comSeres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023March 4, 2024 | benzinga.comSeres Therapeutics's Earnings: A PreviewMarch 2, 2024 | morningstar.comSeres Therapeutics Inc MCRBFebruary 28, 2024 | businesswire.comSeres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024February 27, 2024 | finance.yahoo.comSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceFebruary 27, 2024 | businesswire.comSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceFebruary 26, 2024 | markets.businessinsider.comSeres Therapeutics Appoints Marella Thorell As New CFO Following Retirement Of David ArkowitzFebruary 26, 2024 | finance.yahoo.comSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzFebruary 26, 2024 | businesswire.comSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzFebruary 22, 2024 | benzinga.comSeres Therapeutics Stock (NASDAQ:MCRB), Short Interest ReportFebruary 18, 2024 | msn.comNew Seres 3 arrives in the UK priced from £29,995February 18, 2024 | msn.comMeet the UK's cheapest new electric SUV: the new Seres 3, yours for just under £30kFebruary 7, 2024 | markets.businessinsider.comSell Rating on Seres Therapeutics Amid Underperforming Sales and Financial ChallengesSee More Headlines Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/19/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MCRB CUSIPN/A CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees233Year FoundedN/APrice Target and Rating Average Stock Price Target$6.67 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,090.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,720,000.00 Net MarginsN/A Pretax Margin-90.03% Return on EquityN/A Return on Assets-32.43% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.48 Sales & Book Value Annual Sales$126.33 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.35) per share Price / Book-1.60Miscellaneous Outstanding Shares151,009,000Free Float143,308,000Market Cap$84.55 million OptionableOptionable Beta2.23 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Eric D. Shaff M.B.A. (Age 48)President, CEO & Director Comp: $1.02MDr. Lisa von Moltke M.D. (Age 65)Executive VP & Chief Medical Officer Comp: $725.15kDr. Teresa L. Young Ph.D. (Age 57)R.Ph., Executive VP and Chief Commercial & Strategy Officer Comp: $606.33kKey CompetitorsOramed PharmaceuticalsNASDAQ:ORMPGeneluxNASDAQ:GNLXBarinthus BiotherapeuticsNASDAQ:BRNSConnect BiopharmaNASDAQ:CNTBMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 528,563 shares on 3/11/2024Ownership: 3.977%Goldman Sachs Group Inc.Sold 265,001 shares on 3/1/2024Ownership: 0.299%Price T Rowe Associates Inc. MDBought 31,789 shares on 2/16/2024Ownership: 0.281%David ArkowitzSold 3,939 sharesTotal: $4,254.12 ($1.08/share)Eric D ShaffSold 11,549 sharesTotal: $12,472.92 ($1.08/share)View All Insider TransactionsView All Institutional Transactions MCRB Stock Analysis - Frequently Asked Questions Should I buy or sell Seres Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCRB shares. View MCRB analyst ratings or view top-rated stocks. What is Seres Therapeutics' stock price target for 2024? 3 analysts have issued 1-year price objectives for Seres Therapeutics' shares. Their MCRB share price targets range from $5.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 1,090.7% from the stock's current price. View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts. How have MCRB shares performed in 2024? Seres Therapeutics' stock was trading at $1.40 at the beginning of 2024. Since then, MCRB shares have decreased by 60.0% and is now trading at $0.5599. View the best growth stocks for 2024 here. When is Seres Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MCRB earnings forecast. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings data on Tuesday, March, 5th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.08. The biotechnology company earned $0.06 million during the quarter, compared to the consensus estimate of $0.50 million. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did Seres Therapeutics IPO? Seres Therapeutics (MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MCRB) was last updated on 4/20/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.